Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy

Exclusion Criteria

• •a concurrent medical condition(s) that would prevent compliance or participation or jeopardize the health of the patient
• •hypersensitivity to any component of the formulation
• •active severe infection/inflammation
• •history of transfusion, erythropoietin, \>500 mg intravenous iron administration within 4 weeks prior to screening.
• •history of acquired iron overload.
• •MCV \> 95µm3 or TSAT \> 35%
• •patients with preoperative Hb\<7 g/dl
• •pregnancy or lactation
• •decreased renal function (defined as creatinine clearance \<50 L/min/1.73m2calculated by eGFR(MDRD))
• •chronic liver disease or increase of liver enzymes (ALT, AST) \>5 times the upper limit of normal range